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Abstract
Background: Implantation requires intimate crosstalk between the embryo and uterus
for a successful establishment of pregnancy. Type 2 diabetes mellitus may lead to
implantation failure. The effect of diabetes and its therapeutic drugs on implantation is
still largely unclear.
Objective: To assess the endometrial expression changes of vascular endothelial
growth factor A (VEGFA) and leukemia inhibitory factor (LIF), at the time of implantation
in diabetic rats following treatment with Metformin and Pioglitazone.
Materials and Methods: Twenty-eight 6-8-wk-old Wistar female rats weighing 200-
250 gr were divided into four groups (n = 7/each). Type 2 diabetes was induced and
Metformin and Pioglitazone were applied for 4 wk. The expression of VEGFA and
LIF was measured by real-time reverse transcription-polymerase chain reaction and
Western blot.
Results: The relative expression of VEGFA transcript was higher in the diabetic
(p = 0.02) and Metformin-treated (p = 0.04) rats compared to the control group.
Furthermore, the VEGFA transcript level significantly reduced in Pioglitazone-treated
diabetic rats (p = 0.03). LIF expression was elevated in the Metformin- and the
Pioglitazone-treated rats and reduced in the diabetic group in comparison with the
control group. Compared to the diabetic rats, the expression of LIF was significantly
elevated in the Metformin- (p = 0.01) and Pioglitazone-treated (p = 0.03) groups.
Conclusion: The expressions of LIF and VEGFA were altered in diabetic rats during
implantation which may be associated with diabetic-related infertility. Pioglitazone is
able to restore the VEGFA and LIF expressions to their baseline levels more efficiently
than Metformin.
Key words: Embryo implantation, Leukemia inhibitory factor, Vascular endothelial
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1. Introduction
Type 2 diabetes mellitus (T2DM) is caused
by the insulin resistance in tissues and cells (1).
Although the onset of T2DM is thought to be in
the older ages, this condition also affects younger
adults in the present days (2). The prevalence
of diabetes mellitus is almost equal among male
and female patients in different age groups (3);
however, T2DM affects younger females at their
fertile ages (< 40 yr) more than males (2).
The high level of serum insulin in T2DM impairs
ovarian function during embryo implantation
and is considered as a known factor affecting
fertility rate in normal pregnancies (4). However,
the regulatory role of other molecules such as
hormones, growth factors, transcription factors,
cytokines, lipid metabolites, and developmental
genes in the dynamic of the highly complex
embryo implantation process in the context of
diabetes is yet to be fully elucidated (5). Leukemia
inhibitory factor (LIF) is a cytokine mainly produced
by the endometrial gland and necessary in making
the endometrial epithelium receptive to blastocyst
attachment (6). The vascular endothelial
growth factor A (VEGFA) is a key regulator of
angiogenesis and vascular function in the
endometrium whose contribution to the
implantation process has been well-established
(7). Aberrant expression of both LIF and VEGFA
has been previously reported in the context
of diabetes. Changes have been reported in
LIF expression in the endometrium, myoblasts
and osteoblasts (8, 9), and VEGFA has been
associated with the development of retinopathy,
neuropathy, nephropathy and cardiovascular
diseases in diabetic conditions (10).
Pioglitazone and Metformin are the two
common drugs generally recommended for
diabetic patients (11). Although it seems that these
two drugs have beneficial effects on improving
the reproductive and metabolic outcomes for
women with polycystic ovary syndrome (12),
their precise molecular effects on endometrial
receptivity needs to be clarified.
There have been studies assessing the
expression of LIF and VEGFA as implantation
modulators (7, 13, 14); however, the expression
changes of these molecules in diabetic conditions
and the effects of diabetes treatment drugs on
the endometrial expression of these molecules
have not been well-understood. Therefore, the
current study aimed to assess the endometrial
expression changes of LIF and VEGFA at the
time of implantation in diabetic rats following the
treatment with Metformin and Pioglitazone.
2. Materials and Methods
2.1. Animal models
This experimental study was conducted on
6-8-wk-old Wistar rats weighing 200-250 gr
provided by the Pasteur Institute of Iran. The
animals were kept in standard conditions: 20-22°C
in a temperature-controlled room, with 40-70%
humidity; they were exposed to 12-hr light/dark
cycle with free access to standard water and
food. They were housed in the central animal
house laboratory of Isfahan University of Medical
Sciences.
2.2. Diabetes induction and
verification tests
Type 2 diabetes was induced by a combination
of Nicotinamide (NA, Sigma-Aldrich, Germany)
and Streptozotocin (STZ, Sigma-Aldrich, Germany)
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at a dose of 200 mg/kg and 60 mg/kg of body
weight, respectively, via two intraperitoneal
injections over 15 min (15). To verify the diabetes
induction, fasting blood sugar (FBS) was tested
from the dorsal vein of the rats using a glucometer
(HemoCue Glucose 201+, Sweden) three days
after the injection. FBS > 250 mg/dl was
considered as diabetic animal models (16).
2.3. Study design and sample
collection
Twenty eight rats were randomly divided into
four groups. The first group was the control group
(Ι), including healthy rats without any intervention.
The second group consisted of NA-STZ-induced
type 2 diabetic rats without any treatment (IΙ)
(FBS ≥ 250 mg/dl). The third group comprised of
type 2 diabetic rats treated with 100 mg/kg/day
Metformin (ΙΙΙ) (Sobhan, Iran) (17), and the fourth
group was type 2 diabetic rats treated with 20
mg/kg/day Pioglitazone (IV) (Sobhan, Iran) (18)
(Figure 1). Animals were kept in diabetic conditions
for 4 wk (more than one sexual cycle). The
hypoglycemic drugs were applied by orogastric
gavage for another 4 wk. During all diabetic
conditions and treatment procedures, FBS
level was controlled by glucometer (HemoCue
Glucose 201+, Sweden) and glucose reagent
strips (ACCU-CHEK Active, Germany) every four
days.
In the next step, on the 52nd day, two
female rats of each group were mated with
a male rat and vaginal plug was checked
the following morning. The day on which
the vaginal plugs were observed or vaginal
smears showed spermatozoa was considered
as the first day of pregnancy. On the third
night, rats fasted overnight, were anesthetized
by intraperitoneal injection of Ketamine
Hydrochloride (ROTEXMEDICA, Germany) and
Xylazine Hydrochloride (Daroupakhsh, Iran)
on the following day (50 mg/kg and 7 mg/kg,
respectively), thereafter, they were sacrificed in
sterile conditions on the fourth day of pregnancy,
the day of implantation (19) (Figure 2). Uterine
horns were surgically removed, and all samples
were snap-frozen in liquid nitrogen and stored at
-80°C for further analysis.
2.4. Total RNA isolation and cDNA
synthesis
Total RNA was extracted from isolated
 endometrial tissue using RNX-plus (Sinaclon,
AryoGenBiopharma Complex. Iran) based on
the manufacturer’s protocol. RNA integrity was
determined by 1% agarose gel electrophoresis.
Total RNA concentration of each sample was
estimated using a NanoDrop device (Nanolytik,
Germany) at an optical density of 260 nm
and stored at -80°C for the next step. DNase
treatment was performed in order to omit
genomic DNA in the RNA samples by DNase
set (Fermentas, Lithuania). cDNA synthesis was
performed using 1 µg of total RNA, as previously
prepared, by means of PrimeScriptTM RT reagent
Kit (TaKaRa, Kusatsu, Japan) as stated in the
protocol.
2.5. Quantitative real-time polymerase
chain reaction
The relative expression levels of VEGFA and
LIF genes were determined by quantitative
real-time reverse transcription-polymerase
chain reaction (RT-PCR) in comparison with β-
actin as a reference gene. The primers were
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designed using GeneRunner software (version
4.0; Hastings Software. Inc. Hastings, US) and
the specificity of each primer was tested by
BLAST (http: //blast. ncbi.nlm.nih.gov/Blast.cgi).
The list of the primers is shown in Table
I.
Real-time PCR was carried out by Applied
BiosystemsStepOnePlusTM instrument using
RealQ Plus ×2 Master Mix, green (high ROX)
(AMPLIQON, Denmark). Standard cycling
protocol was applied to perform Real-time PCR.
Amplification condition included: denaturation at
95°C for 10 min, denaturation at 95°C for 15 sec,
annealing at the specific temperature for each
gene (according to Table I) for 60 sec, followed
by extension for 15 sec at 72°C for 40 cycles. To
minimize experimental errors, all samples were
tested in a triplicated manner. Gene expression
assessment was performed using the 2−ΔΔCT
method (20).
2.6. Protein extraction and Western
blot analysis
One hundred mg of uterus tissue was
homogenized in 1 ml of cold RIPA buffer
(Radioimmunoprecipitation assay buffer)
(Cytomatingene, Iran) according to the
manufacturer’s protocol. The samples were
incubated on ice for 30 min, followed by
centrifugation at 27,000 g for 20 min. According to
the manufacturer’s instructions, the supernatant
contains total proteins. Protein concentration
quantification was performed using Bradford
assay. Polyacrylamide gel electrophoresis was
conducted using 10% SDS Polyacrylamide
gel, and the samples were then moved to
Nitrocellulose membranes (Bio-Rad, US). The
membranes were blocked with 5% skimmed milk,
blotted with rabbit anti-LIF (Cat. no. STJ29846,
St John’s Laboratory, United Kingdom) and
rabbit anti-VEGFA (Cat no. ABS82, Merck,
US) primary antibodies (dilution of 1:250), and
incubated overnight at 4°C. Next, the membranes
were washed three times for 15 min with PBS
containing 0.05% Tween 20 and incubated with
mouse anti-rabbit IgG - HRP secondary antibody
(Cat. No. sc-2357, Santa Cruze, Almania) at a
dilution of 1:1,000 at room temperature for 90
min. Clarity Western ECL Substrate Detection
Reagent (Cat. no. Bio-Rad, 170-5060, US)
was used to visualize the blots under SABZ
biomedical chemiluminescent system (SABZ
Biomedicals, Iran). The densitometry of bands
was normalized to β-actin (Cat. no. ab8226;
Abcam, US) using Image software, version 1.8 (21)
(http://rsb.info.nih.gov/ij/).
Table I. Real-time primer sequences














LIF: Leukemia inhibitory factor; VEGFA: Vascular endothelial growth factor-a; bp: Base pair
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Figure 1. Animal grouping: I: control group; II: type 2 diabetic rats without any treatment; III: type 2 diabetic rats treated with
Metformin; IV: type 2 diabetic rats treated with Pioglitazone. STZ, Streptozotocin; NA, Nicotinamide.
Figure 2. Study design. Animals were kept in diabetic conditions for 4 wk. Drugs were applied for another 4 wk. On the 52nd day,
female rats were mated with male rat. On the third night, rats fasted overnight, were anesthetized on the following day, and then
sacrificed in sterile conditions on the fourth day of pregnancy.
2.7. Ethical consideration
All animal experiments complied with the
principles of the Declaration of Helsinki. All
experimental procedures were approved by the
Isfahan University of Medical Sciences Institutional
Animal Ethical Committee (IR.MUI.REC.1396.3.366).
2.8. Statistical analysis
All statistical analyses were performed using
the SPSS software, version 20.0 (SPSS Inc.,
US). Kolmogorov-Smirnov test was used to test
the normality of the data. Real-time PCR and
Western blot were repeated at least three times.
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All values were presented as mean ± standard
error of the mean (SEM). Analysis of Variance
(ANOVA) with post-hoc multiple comparisons were
performed to detect statistical significance which
was considered as p < 0.05.
3. Results
3.1. The effect of Metformin and
Pioglitazone treatment on blood
glucose levels
Four weeks following the induction of diabetes
(after the fixation of diabetes in animals), drug
treatment was commenced for the two groups
of animals whose blood glucose levels were
controlled once every four days. As described
elsewhere, on day 0, the FBS levels of groups IΙ,
IΙI, and ΙV before starting the drug treatment were
significantly higher than those in the group Ι. Four
days after the drug therapy, the FBS levels in both
IΙI and ΙV groups showed a significant decrease
compared to the group ΙΙ. This reduction continued
such that on day 12, the FBS levels of IΙI and ΙV
groups were not significantly different from those
in the group Ι (22).
3.2. VEGFA expression at the
transcript and protein levels
As shown in Figure 3, in comparison with group
Ι, the relative expression level of VEGFA transcript
was significantly higher in the diabetic (p = 0.02)
and Metformin-treated (p = 0.04) (groups II and III)
rats. Pioglitazone-treated (group IV) rats showed
similar levels of VEGFA compared with group
Ι. Furthermore, although the VEGFA transcript
level was not statistically different between the
untreated (group II) and the Metformin-treated
(group III) diabetic rats, it was significantly reduced
in the Pioglitazone-treated diabetic (group IV) rats
(p = 0.03). The same trend was observed at the
protein level of VEGFA although none of afore
mentioned changes were statistically significant
(Figure 4).
3.3. LIF expression at the transcript
and protein levels
The relative expression of LIF transcript
decreased (though not significantly) in group
ΙI compared to group Ι (p = 0.07). Moreover,
compared to group Ι, the LIF expression was
elevated (not statistically significant) in groups III
and IV rats. Compared to group II, the expression
of LIF transcript was significantly elevated in the
ΙΙΙ (p = 0.01) and ΙV (p = 0.03) groups (Figure 5).
The same trend was observed at the protein
level of LIF although compared to group Ι,
the Metformin-treated (group III) rats showed
significantly higher levels of LIF protein (Figure
6).
Figure 3. Relative expression of VEGFA transcript in rat endometrium at the time of implantation. The relative expression of
VEGFA gene was normalized to β-actin using 2−ΔΔCT method. All values are presented as Mean ± SEM. P < 0.05 was considered
statistically significant. Lowercase letters indicate the statistical significance as follows: compared to control (Ι) (a), untreated
diabetic (ΙΙ) (b), and Metformin-treated diabetic (ΙΙΙ) (c) groups. Dia, Diabetic; Met, Metformin; Pio, Pioglitazone.
Page 718 https://doi.org/10.18502/ijrm.v13i9.7666
International Journal of Reproductive BioMedicine VEGFA and LIF expression in a diabetic rat model
 
Figure 4. Relative expression of VEGFA protein in rat endometrium at the time of implantation. Western blot image of VEGFA and
β-actin (as an internal control) proteins (A). The relative expression of VEGFA protein level was quantified by image J software
(B). All values are presented as Mean ± SEM. P < 0.05 was considered statistically significant. Dia, Diabetic; Met, Metformin; Pio,
Pioglitazone.
Figure 5. Relative expression of LIF transcript in rat endometrium at the time of implantation. The relative expression of LIF gene
was normalized to β-actin using 2−ΔΔCT method. All values are presented as Mean ± SEM. P < 0.05 was considered statistically
significant. Lowercase letters indicate the statistical significance as follows: compared to untreated diabetic group (II) (b). Dia,
Diabetic; Met, Metformin; Pio, Pioglitazone.
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Figure 6. Relative expression of LIF protein in rat endometrium at the time of implantation. Western blot image of LIF and β-actin
(as an internal control) proteins (A). The relative expression of LIF protein level was quantified by image J software (B). All values are
presented as Mean ± SEM. P < 0.05 was considered statistically significant. Lowercase letters indicate the statistical significance
as follows: compared to control (I) (a) and untreated diabetic (II) (b) groups. Dia, Diabetic; Met, Metformin; Pio, Pioglitazone.
4. Discussion
There is an association between the diabetic
status and infertility in women, the main mechanism
is yet to be fully fathomed. Moreover, the role of
LIF and VEGFA in the implantation process
and their aberrant expression in different
tissues in diabetic condition has been reported.
However, endometrial LIF and VEGFA expressions
modulation during implantation in the context of
diabetes is not well-understood. Accordingly, we
aimed to investigate the endometrial expression
changes of LIF and VEGFA at the time of
implantation in diabetic rats following the treatment
with Metformin and Pioglitazone.
VEGFA levels were observed to increase
in the endometrial tissues in the diabetic
conditions compared to group Ι. In accordance
to our results, but in in vitro settings, Gu and
colleagues observed that high glucose increased
the percentage of VEGF+ uterus endometrial
cancer cells, inducing VEGF secretion expression
in cancerous cell lines (23). Similarly, Zeybek
and colleagues showed that STZ-induced
diabetic conditions significantly increased the
Vegf expression in the uterine sections of
diabetic rats, probably leading to abnormal
angiogenesis (24). In contrast to the present
study, their diabetic model was diabetes type
1, and they did not simulate the implantation
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conditions as their female rats did not mate with
males.
In the present study, Metformin reduced (though
not significantly) the diabetic-overexpression of
VEGFA. In a similar manner, Yi and co-workers
showed that the total expression of VEGFA was
not reduced by Metformin treatment, following
STZ-induced diabetic retinopathy (25). However,
their diabetic model was type 1 diabetes, and
they merely assessed VEGFA expression in
mouse eyes. We further showed that Pioglitazone
significantly reduced VEGFA expression compared
to untreated diabetic rats. In the same manner and
in a rat model of type 2 diabetic nephropathy, Xu
and colleagues demonstrated that Pioglitazone
can significantly reduce the hyperactivation
of VEGFA in kidneys (26). To the best of our
knowledge, there is no published report assessing
endometrial VEGFA expression in the context of
type 2 diabetes and treatment with Metformin and
Pioglitazone during implantation.
Moreover, following the treatment with
Metformin and Pioglitazone, we studied the
endometrial expression changes of LIF at the
time of implantation in a diabetic rat model. We
observed that LIF expression was insignificantly
reduced in the diabetic conditions. Similar to
the present study, Albaghdadi and colleagues
reported that LIF expression was downregulated
in the uterine of nonobese diabetic mice in pre-
and post-implantation processes (14). In contrast
to the present findings and in a different tissue
type, Broholm and co-workers observed that LIF
expression was upregulated in T2DM condition in
human muscle biopsy, although LIF downstream
signals were impaired (9). However, our study is
the first to investigate the LIF expression in the rat
endometrium in the T2DM conditions.
In the current study, we further observed
the upregulation of LIF following the treatment
with Metformin and Pioglitazone in diabetic
conditions. As far as we are concerned, no study
has investigated the effect of Metformin and
Pioglitazone on the endometrial expression of LIF
in diabetic conditions.
Despite our novel findings, there existed certain
limitations, such as the low number of rats in
each group, possibly affecting the strength of the
study. Moreover, the pregnancy of animals could
be followed-up to investigate the molecular effects
of drug treatments on pregnancy outcomes.
5. Conclusion
Endometrial expression of LIF and VEGFA is
altered in diabetic rats during implantation which
may be associated with diabetic-related infertility. It
was further shown that Pioglitazone is able to more
efficiently restore both VEGFA and LIF expressions
to their baseline levels compared with Metformin.
Further investigations are required to demonstrate
the molecular mechanisms behind these gene
expression alternations, which may play a key role
in the interplay between diabetes and implantation
failure.
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